By Courtney A. Washington, DO | Board-Certified Family Medicine Physician | Ask Dr. Co Women's Health | Menopause | Behind the Science | Updated October 19, 2026 Is hormone replacement therapy safe, or are the risks too great? Hormone replacement therapy (HRT) is one of the most effective treatments for menopausal hot flashes and night sweats. Its safety depends on the hormone, delivery method, timing, and individual medical history. New research and FDA labeling changes are challenging longstanding assumptions, but hormone therapy is neither universally dangerous nor a miracle treatment. Why Are We Finally Talking Openly About Menopause? Imagine being at the height of your career but suddenly struggling to remember details during meetings, waking up exhausted, gaining weight despite maintaining your usual routine, or experiencing changes in intimacy that strain your relationship. Now imagine being told it’s simply part of getting older. For many women, that’s been the experience of perimenopause and menopause. For decades, hormone replacement therapy carried considerable controversy following the 2002 Women’s Health Initiative (WHI), which raised concerns about breast cancer, cardiovascular disease, and blood clots. But medicine evolves. In February 2026, the FDA approved significant labeling changes for certain menopausal hormone therapies. Meanwhile, newer research is helping clarify how specific hormones, treatment timing, and delivery methods influence outcomes. Even the public conversation is changing. Actress Halle Berry has openly discussed her menopause experience and advocated for better education and research. Women are finally talking about menopause openly—and it’s long overdue. But with greater awareness comes another challenge: separating scientific evidence from misinformation. Let’s address some of the biggest myths. Myth #1: Hormone Replacement Therapy Causes Breast Cancer in Every Woman Fact: Breast cancer risk differs according to the hormone regimen, duration of use, and individual risk factors. The Women’s Health Initiative studied different hormone combinations, including oral conjugated equine estrogen alone and estrogen combined with medroxyprogesterone acetate. A 2020 JAMA analysis found different breast cancer outcomes between these groups. Women with a prior hysterectomy receiving estrogen alone experienced lower breast cancer incidence during long-term follow-up than those receiving placebo. In contrast, women receiving estrogen combined with medroxyprogesterone acetate experienced higher breast cancer incidence. These findings do not mean estrogen prevents breast cancer in everyone. They demonstrate that estrogen-only therapy and estrogen-progestogen combinations do not necessarily carry identical risks. Personal cancer history, formulation, and treatment duration remain essential considerations. Myth #2: The FDA Removed the Black Box Warning, So HRT Is Completely Safe Fact: The FDA changed how certain risks are communicated. It did not eliminate those risks. In November 2025, the FDA announced plans to revise longstanding hormone therapy warnings. On February 12, 2026, the agency approved updated labeling for six products, removing cardiovascular disease, breast cancer, and probable dementia statements from their boxed-warning sections. That’s significant. But important risks remain described elsewhere in relevant prescribing information. Systemic estrogen-only products also retain an endometrial cancer boxed warning because women with a uterus generally require adequate progesterone or progestogen protection. The FDA’s decision creates an opportunity for more informed conversations—not a declaration that hormone therapy is appropriate for everyone. Myth #3: Starting Hormone Therapy Early Prevents Heart Disease and Dementia Fact: Timing may influence the benefit-risk balance, but hormone therapy has not been proven to prevent cardiovascular disease or dementia. Researchers have long investigated the timing hypothesis, which proposes that starting HRT closer to menopause may produce different cardiovascular outcomes than beginning treatment many years later. For many healthy women younger than 60 or within 10 years of menopause onset, the benefit-risk balance for treating symptoms is generally more favorable. However, a June 2026 systematic review of 17 randomized controlled trials found insufficient evidence that HRT prevents cardiovascular disease, cancer, cognitive decline, or depression in younger menopausal women. That doesn’t diminish its effectiveness for treating symptoms. We can recognize hormone therapy’s benefits without claiming it prevents diseases that have not been proven preventable through HRT. Myth #4: Hormone Therapy Inevitably Causes Dementia Fact: The relationship between HRT and cognitive health is more complicated than previously believed. A December 2025 systematic review and meta-analysis in The Lancet Healthy Longevity evaluated research involving more than one million participants. The investigators found no statistically significant overall association between menopausal hormone therapy and dementia or mild cognitive impairment. However, these findings do not erase earlier randomized trial evidence of increased dementia risk when certain hormone therapies were initiated in older women. What Questions Should Researchers Investigate Next? Here’s where I think the science becomes particularly interesting. What would happen if researchers followed women who began appropriate hormone replacement earlier in their menopausal transition? Could treatment influence the trajectory of age-related cognitive decline, even if it doesn’t completely prevent dementia? Would the findings differ among women with a strong family history of dementia? And what about women who experience premature ovarian insufficiency or undergo surgical removal of their ovaries before the typical age of menopause? These questions deserve greater scientific attention. Women experiencing early estrogen loss represent an especially important population because the duration and timing of hormone deficiency differ from those of women undergoing menopause at the usual age. Research has examined some of these populations, but adequately powered long-term randomized studies addressing dementia prevention remain limited. We should not promise that early hormone therapy prevents dementia. But we should absolutely continue investigating whether timing, formulation, and the reason for estrogen loss influence long-term cognitive outcomes. Myth #5: Bioidentical Hormones Are Always Safer Than Synthetic Hormones Fact: Certain bioidentical formulations may offer safety advantages, but the delivery method also matters. Bioidentical hormones have the same molecular structure as hormones naturally produced by the body. Examples include estradiol, micronized progesterone, and testosterone. A systematic review published in Archives of Gynecology and Obstetrics in 2023 analyzed 51 studies comparing oral and transdermal hormone therapy. The clearest safety difference involved blood clots. Evidence favored transdermal estrogen over oral estrogen regarding venous thromboembolism risk. That is clinically meaningful, although more high-quality randomized studies are needed. However, those findings concern the route of estrogen
